SEC Form 4 · accession 0001114220-18-000003
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 8, 2018 · 6:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 5, 2018 | S | 1,067 | $4.69 | D | 367,620 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of a total of 1,067 shares of common stock was made in order to satisfy Mr. Madison's income tax withholding obligation upon the vesting of 2,822 shares of restricted stock on January 4, 2018. Mr. Madison had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- F2Includes 214,060 shares of restricted stock.